Studies in adults with pulmonary edema (5-7) have shown intravenous furosemide on the body water compartments variable effects of furosemide on plasma volume. Davidor et al.
4 h after an intravenous dose of furosemide (1 mglkg). All pulmonary edema who had either normal or decreased renal infants had a brisk diuresis in the first hour after the dose, function. The patients who had normal renal function, as indibut urine output was no greater during the 24-h period cated by a good diuresis, had no change in plasma volume 4 to after the dose than during the preceding 24-h period. Total 6 h after a single intravenous dose of furosemide. Patients who body water, extracellular water, and interstitial water were did not have a good diuresis had a rise in plasma volume.
significantly decreased 4 h after furosemide. There was no
There have been no similar studies in infants. Infants with change in plasma volume, red cell volume, or total blood BPD are often fluid restricted with the hope that this will reduce volume (Pediatr Res 26: 121-124, 1989) pulmonary edema. It would be of practical value to know whether furosemide causes a decrease in plasma volume in these Abbreviations infants, because hypovolumeemia might compromise organ perfusion and activate the compensatory mechanisms that stimulate BPD, bronchopulmonary dysplasia water and sodium retention. Our study was undertaken to assess TBW, total body water the effects of a single intravenous dose of furosemide on the IW, interstitial water plasma volume and other body water compartments of infants ECW, extracellular water with BPD. PV, plasma volume CBS, corrected bromide space Br, bromide
MATERIALS AND METHODS

IW, interstitial water BV, blood volume
Nine infants with BPD were studied (Table 1) . Their birth wt ranged from 0.57 to 2.24 kg (median 0.74 kg), with gestational D20, deuterium oxide ages from 24 to 36 wk (median 27 wk). At the time of study ICW, intracellular water Hct, hematocrit their body wt ranged from 0.92 to 3.98 kg (median 2.12 kg); their ages were from 3 1 to 130 d (median 65 d). BPD was RCV, red cell volume diagnosed if an infant still required supplemental oxygen or OD, optical density mechanically assisted ventilation beyond 21 d of age and had typical changes of BPD on chest x-ray. Infants who were receiving chronic diuretic therapy or who had received any furosemide within the previous 48 h were excluded, as were infants with Infants with BpD have interstitial pulmonary edema (1). Fu-abnormal renal function or major congenital anomalies. The rosemide has been shown to improve lung function and speed study was approved by the Human Subjects Review Committee recovery of these infants (2-4), but the mechanism of these of the University of Iowa, and informed consent was obtained effects is not known. Although the water mobilized and excreted from the parents of each subject. after furosemide administration is assumed to be extracellular in
The experimental period lasted 52 h. The rate of fluid intake origin, little is known about the effects of furosemide on specific was not standardized among infants, but in each case the intrabody water compartments in health and disease. venous infusion rate or enteral feeding volume was not changed during the 52-h experimental period. within that period (8, 9) . The D 2 0 and Evans blue dye were
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O'DONOVAN AND BELL administered 4 h after the furosemide. The sodium Br was given 1 h after the furosemide, allowing measurement of Br space 3 h later, at the same time as the determinations of deuterium space and PV. Before each administration of D20, sodium Br, and Evans blue dye, baseline urine, serum, and plasma samples were collected. The infant was weighed before the administration of marker substances on the first day. Deuterium oxide (99.8%, MSD Isotopes, Montreal, PQ) was administered intragastrically in a dose of 1 g/kg except for infant 3, who received this dose intravenously. If a gastric tube was used, the deuterium was flushed through the tube using 3 mL of formula or milk; the regular feeding was then given 20 min later through the same tube. If the intravenous route was used, the stopcock and tubing were flushed with sterile normal saline. The syringe containing the D 2 0 was weighed to the nearest 0.0001 g before and after the dose was given. Urine samples were collected by positioning the infant on a mattress over a recessed collection vessel. We used a modified colostomy bag to collect urine from the larger infants who were more active. The volume and time of each urine sample were recorded. The last urine collected before the administration of D 2 0 and aliquots from each spontaneous voiding between 8 and 24 h after administration were saved for analysis of deuterium oxide enrichment. D 2 0 enrichment in the urine samples was measured using nuclear magnetic resonance spectroscopy (10) . After plotting the logarithm of D 2 0 enrichment in urine versus time, the TBW at the time of administration of the D 2 0 was calculated by extrapolating the urine enrichment back to 0 time using linear regression analysis. The formula for calculation of TBW volume (mL) is shown below.
where D 2 0 dose is the wt (g) of the D 2 0 administered, 18.02 is the mol wt of water, 0.998 is the purity of the D 2 0 administered, 100 is a factor to convert atom percent to atomic ratio, APE D 2 0 is the rise in atom percent excess from predosing to the 0-h extrapolated value, 20.02 is the mol wt of D20, 1.015 is the correction for deuterium distributed into nonaqueous tissues (1 1-14), and 0.993 is the specific gravity of water at body temperature.
At the time of D20 administration on each day of the experiment, sodium Br was also administered either by gastric feeding tube or, in infant 3, intravenously (after the baseline serum sample was drawn). Oral and intravenous administration of sodium Br have been shown to yield similar estimates of ECW in adults (15) . The dose used was 4.5 mL/kg of a 0.333 M solution of sodium Br (1.5 mmol/kg). The exact dose given was determined by weighing the syringe to the nearest 0.000 1 g before and after administration. Three h later, a single serum sample was taken for bromide analysis. From the time of administration of the dose to the second serum sample, all voided urine was pooled for determination of Br excretion. The excreted Br was then subtracted from the dose injected. Br was analyzed using a spectrophotometric method based on the reaction of Br with fluorescein (16) . The ECW was assumed to be equal to the CBS. The CBS (mL) was calculated using the formula below (1 7 [Brls where Br dose is the amount (mmol) of Br given minus the amount excreted in the urine from 0 to 3 h, [Br] , is the serum Br concentration (mM), 0.90 is the fraction of the dose assumed to remain extracellular, 0.95 is the correction for the Donnan equilibrium, 0.94 is the assumed water content in serum, and 1000 is the factor to convert liters to mL. ICW (mL) was calculated as the difference between TBW and ECW. ICW = TBW -ECW Plasma volume was determined as the volume of distribution of Evans blue dye (T-1824) administered intravenously. The dye concentration was measured spectrophotometrically using the method of Nielsen and Nielsen (1 8) as adapted by Parving et al. (19) and Linderkamp et al. (20) . The original method (18) requires that the linear relationship between the negative logarithm of the absorbance of undyed plasma at the wave lengths 620 and 740 nm be established for the spectrophotometer being used. Inasmuch as Evans blue dye has its highest absorbance at 620 nm and no absorbance at 740 nm, the blank OD for each plasma sample can be calculated from the absorbance at 740 nm. We measured these absorbance values for 14 plasma samples from normal infants. The actual absorbance values rather than negative logarithms were plotted against each other (19, 20) . The resulting relation is described by the following equation.
The OD of Evans blue dye at 620 nm for each plasma sample was then calculated using the following formula. OD620 (corrected) = OD620 (measured) -[1.40 OD740 + 0.0101 where OD620 (corrected) is the sample OD at 620 nm (for Evans blue dye alone), OD6Z0 (measured) is the sample OD at 620 nm (for dye and plasma) as experimentally determined, and OD740 is the sample OD at 740 nm.
A blank plasma sample was collected before administration of Evans blue dye on days 1 and 2. Evans blue dye (4.5 mg/mL, Harvey Laboratories, Philadelphia, PA) is packaged in 5-mL vials for injection. We diluted one vial with normal saline 1:5 (vol/vol resulting concentration 0.75 mg/mL) and gave 0.5 mL/ kg intravenously at 0 time on the first day. The precise dose given was determined by weighing the syringe to the nearest 0.000 1 g before and after administration. Ten min later a second sample was taken. Four hours after the dose of furosemide on the secoiAd dsy, Evans blue dye was given again in a similar dose, with blood samples taken before and 10 min after administration. Each injectate was diluted 1: 100 vol/vol with distilled water; the OD at 620 nm and the specific gravity of each resulting solution were measured. PV (mL) was calculated using the following formula.
injectate OD 620 X 100 X injectate dose PV = sample OD620 (corrected) x injectate SG where injectate OD620 is the optical density at 620 nm of the diluted injectate, 100 is the dilution factor for the injectate, injectate dose is the wt (g) of injectate administered, sample OD620 (corrected) is the difference between the OD at 620 nm (corrected as described above) of the 10-min sample and the predosing sample, and injectate SG is the specific gravity (g/mL) of the injectate. IW (mL) was calculated as the difference between ECW and PV.
At the time of each measurement of PV, a venous Hct was obtained. The total BV (mL) was then calculated.
where Hct is the venous Hct (%), 0.98 is the correction for trapped plasma (20) , and 0.91 is the correction for whole body Hct (2 1).
Then RCV (mL) was calculated as follows.
The body water compartments before and after furosemide administration were compared using the t test for paired observations.
RESULTS
All infants had a significant diuresis during the first 4 h after administration of furosemide with the greatest diuresis occurring in the first hour. The mean diuresis during the first 4 h was 7.8 mL. kg-'. h-'. The overall urine output for the 24 h after furosemide administration, however, was not different from the previous 24-h period (Table 1) . Tables 2 and 3 illustrate the values for body water compartments before and 4 h after 1 mg/kg of intravenous furosemide. The results in Tables 2 and 3 are expressed in mL and mL/kg initial body wt, respectively. There was a significant decrease in TBW, ECW, and IW. Although intracellular water tended to increase, this change was not significant. PV, BV, and RCV were unchanged.
Serum Br concentrations 3 h after administration varied from 1.35 to 4.81 mM on d 1, with a mean of 2.52 mM (SD 1.12). Serum concentrations 3 h after dosing on d 2 ranged from 3.74 to 7.13 mM with a mean of 5.31 mM (SD 1.05). No adverse effects of D20, Br, or Evans blue dye were recognized in any of the infants.
DISCUSSION
The measured diuresis during the 4 h between furosemide administration and body water measurement was, on average, 7.8 mL. kg-' . h-', or 3 1 mL/kg. This value is considerably less than the mean decrease in TBW of 87 mL/kg, suggesting error in the determination of urine output or change in TBW or both. Unfortunately, body wt was not measured at the correct times during the study to help resolve this discrepancy. We speculate that our 4-h urine collections underestimated the cumulative diuresis up to the time of deuterium equilibration because of incomplete urine collection and because of urine that had already been cleared by the kidney but not yet voided before the D20 was administered. It is also possible that the magnitude of the change in TBW was overestimated; however, this seems less likely because the decrease in ECW (corrected Br space) was even greater than the decrease in TBW. Furosemide has been previously shown to cause an increase in lung compliance and a decrease in airway resistance in infants with BPD (2). These effects were detectable 1 h after an intravenous dose of furosemide but did not persist. Pate1 et al. (22) also found clinical respiratory improvement that occurred only transiently 2 h after intravenous furosemide. The improvement in lung function produced by furosemide has been postulated to result from increased venous capacitance (23) or mobilization of excess IW from the lungs (24) . Our finding of reduced whole body IW supports the latter hypothesis. Although we did not measure water compartments beyond 4 h after dosing, the 24-h water balance results suggest that the interstitial dehydration induced by furosemide probably lasted only a few hours; the same would presumably be true of the effects on lung function. Although it is possible that changes in intravascular volume occurred closer to the period of maximum diuresis at 1 h (8, 9), we found no change in PV or calculated BV 4 h after the dose of furosemide.
The exact mechanism of fluid mobilization with furosemide is not known. It presumably results from the direct renal effects of furosemide, but it may also involve drug effects on the secretion of prolactin (25) , vasopressin (26) , or atrial natriuretic peptide. The mobilized water arises from the interstitial compartment and is not limited to pulmonary IW. Although the increase in cell water was not statistically significant, our results suggest that there may also have been some movement of interstitial water into cells after furosemide administration.
Furosemide acutely decreased TBW and ECW in infants with BPD. This water was derived primarily from the interstitial space, presumably including lung IW. We postulate that the mobilization of IW observed in this study accounts, at least partly, for the acute effects of furosemide on lung function observed by other investigators (2) (3) (4) .
